Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation

被引：55
作者：
Rosen, HR
Benner, KG
Flora, KD
Rabkin, JM
Orloff, SL
Olyaei, A
Chou, SW
机构：
[1] OREGON HLTH SCI UNIV,DEPT SURG,PORTLAND,OR 97207
[2] VET ADM MED CTR,PORTLAND 97207,DORSET,ENGLAND
[3] OREGON HLTH SCI UNIV,DEPT LIVER TRANSPLANTAT PROGRAM,PORTLAND,OR 97207
来源：
TRANSPLANTATION | 1997年 / 63卷 / 03期
关键词：
D O I：
10.1097/00007890-199702150-00026
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：476 / 478
页数：3
相关论文
共 9 条
[1]   GANCICLOVIR SUSCEPTIBILITIES OF CYTOMEGALOVIRUS (CMV) ISOLATES FROM SOLID-ORGAN TRANSPLANT RECIPIENTS WITH CMV VIREMIA AFTER ANTIVIRAL PROPHYLAXIS [J].
BOIVIN, G ;
ERICE, A ;
CRANE, DD ;
DUNN, DL ;
BALFOUR, HH .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (02) :332-335
[2]   FREQUENCY OF UL97 PHOSPHOTRANSFERASE MUTATIONS RELATED TO GANCICLOVIR RESISTANCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES [J].
CHOU, SW ;
GUENTZEL, S ;
MICHELS, KR ;
MINER, RC ;
DREW, WL .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :239-242
[3]   ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE [J].
CHOU, SW ;
ERICE, A ;
JORDAN, MC ;
VERCELLOTTI, GM ;
MICHELS, KR ;
TALARICO, CL ;
STANAT, SC ;
BIRON, KK .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :576-583
[4]   FAILURE OF HIGH-DOSE ORAL ACYCLOVIR TO SUPPRESS CMV VIRURIA OR INDUCE GANCICLOVIR-RESISTANT CMV IN HIV ANTIBODY-POSITIVE PATIENTS [J].
DREW, WL ;
ANDERSON, R ;
LANG, W ;
MINER, RC ;
DAVIS, G ;
LALEZARI, J .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 8 (03) :289-291
[5]   PREVALENCE OF RESISTANCE IN PATIENTS RECEIVING GANCICLOVIR FOR SERIOUS CYTOMEGALOVIRUS-INFECTION [J].
DREW, WL ;
MINER, RC ;
BUSCH, DF ;
FOLLANSBEE, SE ;
GULLETT, J ;
MEHALKO, SG ;
GORDON, SM ;
OWEN, WF ;
MATTHEWS, TR ;
BUHLES, WC ;
DEARMOND, B .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (04) :716-719
[6]   PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS [J].
ERICE, A ;
CHOU, S ;
BIRON, KK ;
STANAT, SC ;
BALFOUR, HH ;
JORDAN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :289-293
[7]   THE COST IMPACT OF CYTOMEGALOVIRUS DISEASE IN RENAL-TRANSPLANT RECIPIENTS [J].
MCCARTHY, JM ;
KARIM, MA ;
KRUEGER, H ;
KEOWN, PA .
TRANSPLANTATION, 1993, 55 (06) :1277-1282
[8]   Cytomegalovirus prophylaxis in solid organ transplant recipients [J].
Patel, R ;
Snydman, DR ;
Rubin, RH ;
Ho, M ;
Pescovitz, M ;
Martin, M ;
Paya, CV .
TRANSPLANTATION, 1996, 61 (09) :1279-1289
[9]   RANDOMIZED COMPARISON OF GANCICLOVIR AND HIGH-DOSE ACYCLOVIR FOR LONG-TERM CYTOMEGALOVIRUS PROPHYLAXIS IN LIVER-TRANSPLANT RECIPIENTS [J].
WINSTON, DJ ;
WIRIN, D ;
SHAKED, A ;
BUSUTTIL, RW .
LANCET, 1995, 346 (8967) :69-74
1